Nichols R - Search Results

1

A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment.

Lombard L, Ye W, Nichols R, Jackson J, Cotton S, Joshi S. Lombard L, et al. Among authors: nichols r. Headache. 2020 Jul;60(7):1325-1339. doi: 10.1111/head.13835. Epub 2020 Jun 8. Headache. 2020. PMID: 32510611 Free PMC article.

2

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies.

Nichols R, Doty E, Sacco S, Ruff D, Pearlman E, Aurora SK. Nichols R, et al. Headache. 2019 Feb;59(2):192-204. doi: 10.1111/head.13443. Epub 2018 Nov 21. Headache. 2019. PMID: 30462830 Free PMC article. Clinical Trial.

3

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.

Nichols R, Skljarevski V, Dell'Agnello G, Hundemer HP, Aurora SK. Nichols R, et al. J Headache Pain. 2019 Mar 1;20(1):22. doi: 10.1186/s10194-019-0975-2. J Headache Pain. 2019. PMID: 30823868 Free PMC article. No abstract available.

4

Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.

Ford JH, Ye W, Nichols RM, Foster SA, Nelson DR. Ford JH, et al. Among authors: nichols rm. J Med Econ. 2019 Sep;22(9):849-858. doi: 10.1080/13696998.2019.1607358. Epub 2019 May 8. J Med Econ. 2019. PMID: 30977712 Free article.

5

A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe.

Ford JH, Foster SA, Nichols RM, Tockhorn-Heidenreich A, Ye W, Jackson J, Cotton S. Ford JH, et al. J Patient Rep Outcomes. 2020 Jul 6;4(1):53. doi: 10.1186/s41687-020-00221-w. J Patient Rep Outcomes. 2020. PMID: 32632891 Free PMC article.

6

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).

Ford J, Tassorelli C, Leroux E, Wang S, Ayer D, Nichols R, Detke H. Ford J, et al. Among authors: nichols r. Qual Life Res. 2021 Jan;30(1):105-115. doi: 10.1007/s11136-020-02623-1. Epub 2020 Sep 15. Qual Life Res. 2021. PMID: 32930994 Free PMC article. Clinical Trial.

7

Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures.

Ford J, Nichols RM, Ye W, Tockhorn-Heidenreich A, Cotton S, Jackson J. Ford J, et al. Clinicoecon Outcomes Res. 2021 Jul 14;13:647-660. doi: 10.2147/CEOR.S304158. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 34285524 Free PMC article.

8

Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).

Tepper SJ, Ailani J, Ford JH, Nichols RM, Li LQ, Kemmer P, Hand AL, Tockhorn-Heidenreich A. Tepper SJ, et al. Clin Drug Investig. 2022 Mar;42(3):263-275. doi: 10.1007/s40261-021-01115-5. Epub 2022 Jan 18. Clin Drug Investig. 2022. PMID: 35041159 Free PMC article. Clinical Trial.

9

Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials.

Tobin J, Ford JH, Tockhorn-Heidenreich A, Nichols RM, Ye W, Bhandari R, Mi X, Sharma K, Lipton RB. Tobin J, et al. Among authors: nichols rm. J Med Econ. 2022 Jan-Dec;25(1):630-639. doi: 10.1080/13696998.2022.2071528. J Med Econ. 2022. PMID: 35510376 Free article. Clinical Trial.

10

Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).

Tobin JA, Joshi S, Ford JH, Nichols RM, Foster SA, Ruff D, Detke HC, Aurora SK. Tobin JA, et al. J Med Econ. 2022 Jan-Dec;25(1):1030-1038. doi: 10.1080/13696998.2022.2109335. J Med Econ. 2022. PMID: 35971655 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,283 results

Search Page

Filters